Copyright
©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6236-6245
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Table 6 Change in fibrosis stage after anti-viral treatment (76 cases) n (%)
| Fibrosis | SVR (n =32) P = 0.08 | Survived (n =60) P = 0.03 | |
| Progressed | |||
| one stage | 32 (42) | 17 (53) | 27 (45) |
| two stages | 10 (13) | 5 (16) | 9 (15) |
| ≥ three stages | 5 (7) | 1 (3) | 2 (4) |
| Unchanged | 23 (30) | 5 (16) | 17 (28) |
| Improved | 6 (8) | 4 (12) | 5 (8) |
- Citation: Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World J Gastroenterol 2015; 21(20): 6236-6245
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6236.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6236